A former hedge fund manager is justifying his startup company's decision to increase the price of a life-saving drug from $13.50 per pill to $750 by saying it's necessary in order to create better medicine in the future. Martin Shkreli's Turing Pharmaceuticals acquired the drug Daraprim in August, The Guardian reports, which is used to treat toxoplasmosis, an infection that can be fatal when it affects babies born to infected mothers and people with compromised immune systems due to AIDS and certain cancers.